摘要
目前,肺癌已成为对人类健康危害最大的恶性肿瘤,其中非小细胞肺癌(NSCLC)约占肺癌总数的87%,且大部分患者被发现时已进入晚期。中医药在晚期NSCLC的治疗中具有其独特的作用及优势,包括:1)中医药强调个体化治疗,即根据不同患者的基因表达、治疗诉求、经济状况等,进行个体化施治。通过辨病与辩证、内服与外用,调节病患机体功能,提高疗效,降低治疗成本和疾病进展风险;2)中医药与西医治疗相结合,起到减毒增效,降低耐药发生率,调节人体免疫功能,改善预后的作用;3)中医药对于一线治疗结束后或无法接受一线治疗方案的患者,可有效延长无进展生存期,延缓复发,稳定瘤灶,提高生存质量,使患者保持较好的生存状态。本文根据近十年来国内外公开发表的相关文献,综述中医药在治疗NSCLC中的研究进展,分析其作用、优势与不足,总结相关作用规律,为优化NSCLC的临床治疗提供参考。
Currently, lung cancer has become one of the most harmful malignant tumors for human health. Especially, non-small cell lung cancer (NSCLC) accounts for about 87% in all lung cancers, and most patients are diagnosed at an advanced stage. Traditional Chinese Medicine (TCM) exhibits its own unique effects and advantages in the treatment of advanced NSCLC. 1) TCM focuses on the individualized treatment, i.e., the unique treatment plan is formulated for each patient according to his/hergene expression, treatment demand, economic status and so on. Various approaches, such as syndrome differentiation, or internal and external use etc., are adopted to improve the patient’s physical performance and therapy efficacy while reduce treatment cost and disease deterioration risk. 2) The combination of TCM and western medicine can reduce side effects, improve curative efficiency, decrease drug resistance rate, regulate immunity function and improve prognosis for patients. 3) For the patients finished or cannot receive the first-line treatment, TCM can effectively prolong their progression-free survival, delay their recurrence and metastasis, and improve their quality of life to maintain them in a good survival state. Here we review the progress of TCM in treatment of NSCLC according to the domestic and foreign literatures in the past decade. Furthermore, the effects, advantages and disadvantages of TCM in treatment of NSCLC are also discussed. The relevant rules are summarized for optimizing the clinic treatment of NSCLC.
出处
《中医学》
2018年第6期340-347,共8页
Traditional Chinese Medicine
基金
十三五“重大新药创制”科技重大专项(2017ZX09304001)
上海市重中之重临床医学中心和重点学科建设计划(2017ZZ01010)
上海申康医院发展中心临床科技创新项目(SHDC12016114)。
